title: Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication.
abstract: The role of Campylobacter pylori gastritis in dyspepsia could be clarified more readily if reliable eradication therapy were available. Antibiotic monotherapy and combined therapy with an antibiotic agent plus a bismuth compound have yielded poor long-term results. In this study, bismuth-tetracycline-metronidazole triple therapy has been used to eradicate C. pylori infection in 100 consecutive patients who were suffering from either a duodenal ulcer or non-ulcer dyspepsia. Examination of a follow-up endoscopic biopsy at eight weeks after treatment showed an eradication rate of C. pylori of 94%. Of 64 patients whose biopsy samples were free of C. pylori infection at eight weeks and who were available for reassessment, 60 (94%) patients had samples that remained free of C. pylori infection on examination of a repeat endoscopic biopsy at 12-37 months (mean, 19.3 months). It is concluded that "triple chemotherapy" can achieve long-term eradication of C. pylori infection effectively in the majority of treated patients and that the recurrence of duodenal ulcers thus may be diminished.
authors.affiliation: Centre for Digestive Diseases, Five Dock, NSW.
authors.forename: T J
authors.initials: TJ
authors.lastname: Borody
authors.forename: P
authors.initials: P
authors.lastname: Cole
authors.forename: S
authors.initials: S
authors.lastname: Noonan
authors.forename: A
authors.initials: A
authors.lastname: Morgan
authors.forename: J
authors.initials: J
authors.lastname: Lenne
authors.forename: L
authors.initials: L
authors.lastname: Hyland
authors.forename: S
authors.initials: S
authors.lastname: Brandl
authors.forename: E G
authors.initials: EG
authors.lastname: Borody
authors.forename: L L
authors.initials: LL
authors.lastname: George
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002169:Campylobacter Infections / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D004415:Dyspepsia / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000009:adverse effects; D011446:Prospective Studies; D012008:Recurrence; D013752:Tetracycline / Q000008:administration & dosage / Q000009:adverse effects; D013997:Time Factors
chemical_list: D009942:Organometallic Compounds; D008795:Metronidazole; D013752:Tetracycline; C002791:bismuth tripotassium dicitrate